search
Back to results

Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes (LymphoEnergy)

Primary Purpose

Parkinson's Disease, Amyotrophic Lateral Sclerosis, Oxidative Stress

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
deferiprone
placebo
Sponsored by
University Hospital, Lille
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Parkinson's Disease focused on measuring Parkinson's disease, Amyotrophic lateral sclerosis, Peripheral blood mononuclear cells, ex vivo model for oxidative stress, iron metabolism and chelation

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Parkinson's disease according to Movement Disorders Society criteria
  • Amyotrophic Lateral Sclerosis according to El escorial criteria
  • Age and sex matched healthy controls

Exclusion Criteria:

  • Severe comorbidities (cancer, other degenerative diseases, hemopathy, inflammatory diseases)

Sites / Locations

  • Hôpital Roger Salengro, CHRU de Lille

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Parkinson's disease

Amyotrophic lateral sclerosis

healthy age and sex matched controls

Arm Description

ex vivo analysis of lymphocytes from 30 patients with Parkinson's disease with deferiprone and placebo treatment

ex vivo analysis of lymphocytes from 30 patients with Amyotrophic lateral sclerosis with deferiprone and placebo treatment

ex vivo analysis of lymphocytes from 30 healthy age and sex matched controls with deferiprone and placebo treatment

Outcomes

Primary Outcome Measures

hydroxyl radical measured
hydroxypethidine probe with Fluorescence-activated cell sorting

Secondary Outcome Measures

adenosine triphosphate production measured by seahorse
seahorse experimentation
oxygen consumption measured by seahorse
seahorse experimentation
free reactive iron (ferrous iron)
calceine assay
lipid peroxidation measured by Fluorescence-activated cell sorting
flow cytometry with bodipy probe

Full Information

First Posted
August 3, 2016
Last Updated
March 25, 2020
Sponsor
University Hospital, Lille
search

1. Study Identification

Unique Protocol Identification Number
NCT02880033
Brief Title
Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes
Acronym
LymphoEnergy
Official Title
Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
February 2011 (undefined)
Primary Completion Date
October 2019 (Actual)
Study Completion Date
March 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Lille

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Peripheral blood mononuclear cells (PBMC) and platelets could be interesting ex vivo models to study brain diseases. Indeed, there is no access to neurons from patients. However, PBMC can exhibit different physiopathological mechanisms that are ubiquitous (i.e. oxidative stress, mitochondriopathy with energy metabolism, inflammation, protein folding, iron metabolism and programmed cell death ...). The platelets are pivotal in the healing system with large range of growth factors. A new therapeutic concept of conservative iron chelation with deferiprone for neuroprotection is under development. The action of deferiprone on the different mechanisms and notably the oxidative stress are to obtain from a collection of PBMC and platelets from patient having Parkinson's disease and Amyotrophic lateral sclerosis and healthy controls to study ex vivo. PBMC and platelets will be stored for future analyses.
Detailed Description
The study collection of PBMC and platelets from 30 patient having Parkinson's disease 30 patients having Amyotrophic lateral sclerosis and 30 healthy controls. The collection will be performed either by cytapheresis for half of the patient and by collecting the whole blood for the other half. PBMC and platelets will be stored at minus 80°C. PBMC of patients and controls are exposed ex vivo to different pathological condition (mainly Hydrogen peroxide, menadione, hypoxia...) with and without deferiprone to analyse whether the level of oxidative stress (Reactive Oxygen Species and notably hydroxyl radical with hydroxypethidine probe with flow cytometry) is reduced under deferiprone (primary criterion. Secondary analyses will concern the level of iron, the energy metabolism (aerobic versus anaerobic and the level of Adenosine triphosphate production), the type of cell death (apoptosis, autophagy and new programmed cell death: Ferroptosis) and inflammation. Finally, the level of growth factors and their effectiveness will be studied from platelets.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson's Disease, Amyotrophic Lateral Sclerosis, Oxidative Stress, Iron Overload
Keywords
Parkinson's disease, Amyotrophic lateral sclerosis, Peripheral blood mononuclear cells, ex vivo model for oxidative stress, iron metabolism and chelation

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
90 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Parkinson's disease
Arm Type
Active Comparator
Arm Description
ex vivo analysis of lymphocytes from 30 patients with Parkinson's disease with deferiprone and placebo treatment
Arm Title
Amyotrophic lateral sclerosis
Arm Type
Active Comparator
Arm Description
ex vivo analysis of lymphocytes from 30 patients with Amyotrophic lateral sclerosis with deferiprone and placebo treatment
Arm Title
healthy age and sex matched controls
Arm Type
Placebo Comparator
Arm Description
ex vivo analysis of lymphocytes from 30 healthy age and sex matched controls with deferiprone and placebo treatment
Intervention Type
Drug
Intervention Name(s)
deferiprone
Other Intervention Name(s)
FERRIPROX
Intervention Description
to test the action of deferiprone on lymphocytes from patients and controls ex vivo
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
to control the action of placebo on lymphocytes from patients and controls ex vivo
Primary Outcome Measure Information:
Title
hydroxyl radical measured
Description
hydroxypethidine probe with Fluorescence-activated cell sorting
Time Frame
12 months
Secondary Outcome Measure Information:
Title
adenosine triphosphate production measured by seahorse
Description
seahorse experimentation
Time Frame
12 months
Title
oxygen consumption measured by seahorse
Description
seahorse experimentation
Time Frame
12 months
Title
free reactive iron (ferrous iron)
Description
calceine assay
Time Frame
12 months
Title
lipid peroxidation measured by Fluorescence-activated cell sorting
Description
flow cytometry with bodipy probe
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Parkinson's disease according to Movement Disorders Society criteria Amyotrophic Lateral Sclerosis according to El escorial criteria Age and sex matched healthy controls Exclusion Criteria: Severe comorbidities (cancer, other degenerative diseases, hemopathy, inflammatory diseases)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David DEVOS, MD, PhD
Organizational Affiliation
University Hospital, Lille
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Roger Salengro, CHRU de Lille
City
Lille
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes

We'll reach out to this number within 24 hrs